An Ozempic box made by Novo Nordisk, in a pharmacy in London on March 8, 2024.
Hollie Adams | Reuters
Novo Nordisk On Monday, he said that he now offers patients who pay in cash their success of highly successful diabetes Ozempic for less than half of their monthly list price, since medication manufacturers face a growing political pressure to reduce prices in the country.
Patients can pay $ 499 in cash per month for three Ozempic dose sizes. They can obtain the price through platforms that include the official drug website, the Novo Nordisk patient assistance program and the directly launched consumer of the company, the last of which also sends the injection directly to the patient's houses.
The Goodrx medication savings company will also offer Ozempic and its Wegovy weight loss counterpart for $ 499 per month, which makes discounts available in more than 70,000 pharmacies throughout the country, according to a statement by Novo Nordisk.
“We have seen a demand triggered from our consumer base for these very wanted therapies, however, millions of people still lack adequate insurance coverage,” said the Goodrx CEO, Wendy Barnes, in a statement. “With this collaboration, we are taking a significant step in our broader effort to fill the gaps in coverage when insurance falls short.”
Novo Nordisk's cash payment offer will expand access to eligible patients with type 2 diabetes who do not have insurance coverage for weekly injection. In March, the company began offering Wagovy in half of its list price to Americans who pay effective.
The Ozempic list price before insurance and other reimbursements is almost $ 1,350 per month, and has been a frequent objective of political and public setback in recent years. The new offer occurs after President Donald Trump in July sent separate letters to Novo Nordisk and another 16 drug manufacturers, asking them to take measures to reduce the prices of medicines in the US. UU. Among other suggested actions, he urged them to adopt models that sell medications directly to consumers or companies.
The efforts aim to make Ozempic and Wogovy available for more people, while ensuring that patients use the brand medication instead of cheaper compound imitators. These drugs exploded in popularity during an American shortage now resolved from the Semaglutida of Novo Nordisk, the active ingredient in both drugs.
While Ozempic “is well covered in the United States, let's not forget that there are some patients paying for this vital medicine,” said Dave Moore, executive vice president of US operations and global business development in Novo Nordisk, in the statement. “We believe that if even a single patient feels the need to resort to potentially insecure and not approved imitation alternatives, that is too much.”
Eli Lilly Similarly, it has moved to reduce the price of their popular medications of obesity and diabetes for patients who pay effective. The two companies are struggling to dominate the market of so-called GLP-1, which mimic intestinal hormones to suppress appetite and regulate blood sugar.
